ARTMS
ARTMS (now Telix ARTMS) develops the QUANTM Irradiation System and solid targets that enable decentralized cyclotron-based production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64), serving hospital cyclotron operators, radiopharmacies, and radiopharmaceutical manufacturers globally.
- Company typePrivate
- Founded2013
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ARTMS does
ARTMS Inc. (Alternative Radioisotope Technologies for Medical Science) is a Canadian medical technology company that develops the QUANTM Irradiation System (QIS) and a portfolio of proprietary solid targets to enable decentralized, cyclotron-based production of medical radioisotopes. Founded in 2013 by TRIUMF scientists to address projected technetium-99m supply disruptions, ARTMS targets hospital-based medical cyclotron operators, commercial nuclear pharmacies, and radiopharmaceutical manufacturers across North America, Europe, and select Asia-Pacific and Latin America markets. Following its April 2024 acquisition by Telix Pharmaceuticals Limited (ASX: TLX), ARTMS operates as Telix ARTMS, Inc. and functions as the manufacturing and supply-chain backbone for Telix's cyclotron-produced isotope strategy.
The QUANTM platform comprises three integrated components: an automatic 2-way pneumatic transfer system, a compact solid target station, and single-use enriched metal targets (QUANTM-68 Zn-68 for Ga-68, QUANTM-99 Mo-100 for Tc-99m, QUANTM-89 Y-89 for Zr-89, QUANTM-64 Ni-64 for Cu-64). Production volumes significantly exceed conventional generators — 5,000 mCi Ga-68 per 2-hour run, up to 37-40 Ci Tc-99m per 6-hour run, over 50 mCi/hour Zr-89, and over 200 mCi/hour Cu-64 — while avoiding enriched uranium and long-lived radioactive waste. The QIS is compatible with most OEM medical cyclotron platforms and is retrofittable to installed units with minimal operational disruption.
ARTMS operates a hybrid revenue model: one-time QIS hardware sales and installation services combined with recurring consumable target revenue (single-use targets plus proprietary Ni-64 recycling), augmented by regulatory licensing where radiopharmaceutical innovators reference ARTMS's FDA Drug Master Files and Health Canada Type 1 Master Files in their drug applications — most notably Telix's Gozellix (Ga-68 gozetotide), approved by FDA in 2025. Distribution combines direct enterprise sales with an OEM-embedded channel through GE Healthcare's PETtrace 800 series. ARTMS holds global patent rights for cyclotron Tc-99m production, has achieved Health Canada approval, CE marking, and FDA DMF filings, and is ISO 9001 certified.
ARTMS firmographics
Firmographics- Name
- ARTMS
- Legal name
- ARTMS Inc.
- Website
- https://artms.ca
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- ARTMS (now Telix ARTMS) develops the QUANTM Irradiation System and solid targets that enable decentralized cyclotron-based production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64), serving hospital cyclotron operators, radiopharmacies, and radiopharmaceutical manufacturers globally.
- Ownership category
- akta.pro rank
ARTMS industry classification
Industry- Product category
- Medical Isotope Production Equipment
- NAICS
- Irradiation Apparatus Manufacturing (334517), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)
- akta.pro secondary industries
- Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)
Keywords
Where ARTMS is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
ARTMS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- QUANTM Irradiation System (QIS) Hardware Sales: Sale of QIS hardware systems (pneumatic transfer, target station, processing equipment) to cyclotron operators including hospitals, radiopharmacies, and pharmaceutical distributors. Installation and commissioning services included. System is retrofittable to existing cyclotrons with minimal disruption.
- QUANTM Solid Target Consumables: Recurring sale of proprietary solid target consumables (Mo-100, Zn-68, Y-89, Ni-64 targets) to cyclotron operators. Targets are single-use. ARTMS also provides proprietary recycling of Ni-64 targets for reuse, ensuring supply chain continuity.
- Regulatory/DMF Filing Services: ARTMS prepares and files Drug Master Files (DMF) with regulatory bodies (FDA, Health Canada) for cyclotron-produced isotopes, enabling pharmaceutical companies to reference these in their drug applications. This creates a service/embedded relationship with radiopharmaceutical innovators.
- Technology Integration and Licensing to OEM Partners: Licensing of QIS technology to OEM cyclotron manufacturers (e.g., GE Healthcare) for integration into their platforms. Revenue from equipment manufacturers embedding ARTMS technology in cyclotron offerings.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
ARTMS product offering
Product offeringCore offering
ARTMS develops and sells the QUANTM Irradiation System (QIS), a cyclotron-based hardware platform consisting of automatic pneumatic transfer, a compact solid target station, and processing solutions for decentralized production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64). The company also produces and supplies proprietary single-use solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) that pair with the QIS on hospital-based medical cyclotrons. It files Drug Master Files (DMFs) with regulators that radiopharmaceutical innovators reference in their drug applications.
Product overview
ARTMS offers the QUANTM Irradiation System (QIS) as its core platform for decentralized medical isotope production, paired with a portfolio of specialized solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) for producing Gallium-68, Technetium-99m, Zirconium-89, and Copper-64 respectively. The QIS enables hospitals and radiopharmacies with medical cyclotrons to produce these critical diagnostic isotopes locally, eliminating dependence on centralized reactor-based supply. The system integrates with OEM cyclotron platforms and includes automated target processing and purification capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- QUANTM Irradiation System (QIS™): Complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of medical isotopes including Zr-89, Ga-68, Tc-99m, and Cu-64.
- QUANTM-64 (Copper-64)
- QUANTM-99 (Technetium-99m)
- QUANTM-68 (Gallium-68)
- QUANTM-89 (Zirconium-89)
Products and services
- QUANTM Irradiation System (QIS) Complete cyclotron-based isotope production system consisting of automatic 2-way pneumatic transfer, a compact solid target station, and complete solid target processing solutions. Enables decentralized, large-scale, cost-effective production of medical isotopes on hospital-based medical cyclotrons and commercial nuclear pharmacies.
- QUANTM-68 (Gallium-68) Solid Target Single-use Zinc-68 target with silver backing for cyclotron production of Gallium-68. Provides up to 5,000 mCi of Ga-68 per two-hour cyclotron irradiation at optimal energy of 12.7 MeV; dissolution and purification in 40 minutes. Used for PET imaging of neuroendocrine tumors and prostate cancer.
- QUANTM-99 (Technetium-99m) Solid Target Single-use Molybdenum-100 target with copper or tantalum backing for cyclotron production of Technetium-99m. Yields up to 37-40 Ci at optimal 24 MeV and 500 uA over a 6-hour irradiation; dissolution and purification in approximately 2 hours. Approved by Health Canada for clinical use.
- QUANTM-89 (Zirconium-89) Solid Target Single-use Yttrium-89 target with tantalum backing for cyclotron production of Zirconium-89. Yields over 50 mCi per hour at optimal 13 MeV; irradiations can exceed 12 hours; dissolution and purification under 1.5 hours. Used for Immuno-PET imaging in oncology.
- QUANTM-64 (Copper-64) Solid Target Nickel-64 target with rhodium backing and range of Ni-64 mass for cyclotron production of Copper-64. Yields over 200 mCi per one-hour irradiation at optimal energy under 13 MeV; dissolution and purification under 2 hours. Includes proprietary Ni-64 recycling solution for stable supply. Used for oncology PET applications.
Quantifiable outcome
- 99mTc is used in over 50 million diagnostic studies annually worldwide
- +5 more outcomes
Companies that use ARTMS
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
ARTMS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature7 records
ARTMS partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and major.
- POINT BiopharmacoreTri-party co-operation with POINT Biopharma and CanProbe for the development and clinical use of innovative Ga-68-based radiopharmaceuticals in Canada. ARTMS' solid target approach enables 100-fold increase in Ga-68 availability over generator supply. POINT aims to use this supply for next-generation radiopharmaceutical therapies.
- CanProbe (Centre for Probe Development and Commercialization and University Health Network)coreTri-party co-operation with CanProbe (joint venture between CPDC and UHN) and POINT Biopharma for Ga-68 radiopharmaceutical development in Canada. CanProbe enables 100-fold increase in Ga-68 availability using ARTMS QIS compared to generator supply, working with innovators to meet patient needs.
- Isotopia Molecular ImagingmajorSuccessful multi-curie radiolabeling of Isotopia's PSMA-11 prostate cancer imaging kit with over 2 Ci of cyclotron-produced Ga-68 using ARTMS QIS. Demonstrated 6-hour stability and radiochemical purity meeting regulatory standards. Enables near unlimited access to diagnostic product for radiopharmacies.
- TRIUMF, BC Cancer, Centre for Probe Development and Commercialization, Lawson Health ResearchcoreFounding technology collaboration institutions. ARTMS' core technology stems from TRIUMF (Canada's particle accelerator centre), BC Cancer, CPDC, and Lawson Health Research. Early stage research funded by NSERC and the Isotope Technology Acceleration Program (ITAP). These institutions participated in Canadian consortium for Health Canada submission.
- Telix Pharmaceuticals LimitedcoreManufacturing collaboration for high-activity Ga-68 production using ARTMS QIS for Telix's prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11). ARTMS provides cyclotron technology and Zn-68 target irradiations; Telix provides radiochemistry expertise. Collaboration used in marketing authorization applications. ARTMS subsequently acquired by Telix in April 2024.
- ImaginAbmajorStrategic partnership to explore novel radiochemistry manufacture of ImaginAb's lead asset 89Zr CD8 immunoPET agent. ARTMS' QIS platform produces Zr-89 for labeling of molecular targeting ligands such as antibodies for Immuno-PET imaging.
- Odense University Hospital and University of Southern DenmarkmajorCollaboration with scientists and clinical researchers from Odense University Hospital and University of Southern Denmark. Demonstrated record Ga-68 production levels from a single short-duration irradiation of QUANTM 68Zn Target Plates. Data presented at European Association of Nuclear Medicine conference.
- GE HealthcarecoreStrategic partnership for ARTMS' QUANTM99 Irradiation System (QIS) integrated with GE's PETtrace 800 series medical cyclotron platform. Includes agreement for first European QIS installation and joint research into expanding isotope production (Cu-64, Ga-68). ARTMS supplies equipment, technologies, and research; GE Healthcare provides platform access and distribution.
- Alliance MedicalcoreStrategic partnership to demonstrate and gain regulatory marketing approval for alternative non-reactor Tc-99m supply within the United Kingdom. ARTMS provides hardware, know-how, and proprietary consumables to enable and demonstrate cyclotron-produced Tc-99m. Reduces UK reliance on foreign reactor-based production and enriched uranium.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
ARTMS competitors and assessment
Company assessmentDirect peers
- IBA Radiopharma Solutions: IBA is a major manufacturer of medical cyclotrons (similar to GE Healthcare's PETtrace), providing both the cyclotron hardware and increasingly integrated targetry and processing solutions. IBA competes directly with ARTMS on integrated isotope production platforms.
- NorthStar Medical Radioisotopes: NorthStar is the most direct competitor to ARTMS in non-reactor Mo-99/Tc-99m production, using electron accelerators rather than cyclotrons. Both companies pursue the same end goal of decentralizing Tc-99m supply away from aging nuclear reactors, addressing the same customer base of radiopharmacies and hospitals.
- SHINE Medical Technologies: SHINE pursues commercial-scale Mo-99 production using fusion neutron technology, also targeting the same reactor-independent Tc-99m supply opportunity. Both companies compete for radiopharmacy and hospital customers seeking non-reactor isotope supply.
Broad incumbents
- Lantheus Holdings: Lantheus is a major radiopharmaceutical company with established diagnostic imaging products (e.g., PYLARIFY PSMA-PET, Definity). Both companies serve the same end customers in nuclear medicine; ARTMS provides upstream isotope production infrastructure while Lantheus provides finished imaging agents.
- Telix Pharmaceuticals: Telix is ARTMS's parent company post-April 2024 acquisition. As both a strategic acquirer/parent and a leading radiopharmaceutical innovator (Gozellix, Illuccix), Telix represents the vertical integration of ARTMS's isotope supply into commercial drug products.
- Curium Pharma: Curium is one of the largest global manufacturers of diagnostic radiopharmaceuticals and SPECT/PET tracers. As both a potential customer of ARTMS isotope production technology and a competitor in the broader radiopharma supply chain, Curium is a critical industry peer.
- Bracco Imaging: Bracco is a large diagnostic imaging company offering contrast agents and radiopharmaceuticals. Like Lantheus, Bracco is both a potential customer for ARTMS-produced isotopes and a peer in the broader diagnostic imaging supply chain.
Regional players
- Cardinal Health Nuclear Pharmacy Services: Cardinal Health operates one of the largest US nuclear pharmacy networks, distributing radiopharmaceuticals to hospitals and clinics. It is a primary US distribution channel for SPECT/PET tracers and a potential large-scale customer of ARTMS QIS installations.
Emerging players
- ITM Isotope Technologies Munich: ITM is a specialized radiotherapeutics company developing Lu-177 and other therapeutic isotopes, with manufacturing capabilities including cyclotron-based production. It overlaps with ARTMS in isotope production technology for emerging therapeutic applications including potential Ac-225 supply.
- PETNET Solutions (Siemens Healthineers): PETNET is a large North American radiopharmacy network operating Siemens cyclotrons to produce PET tracers including Ga-68. It is both a potential customer of ARTMS QIS for distributed production and a peer in radiopharmacy services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ARTMS social profiles
Digital presenceARTMS compliance and trust
Trust signalCompliance3 records
ARTMS financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARTMS leadership team
Management profileNumber of profiles
Profiles10 records
ARTMS funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARTMS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARTMS
What does ARTMS do?
ARTMS develops and sells the QUANTM Irradiation System (QIS), a cyclotron-based hardware platform consisting of automatic pneumatic transfer, a compact solid target station, and processing solutions for decentralized production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64). The company also produces and supplies proprietary single-use solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) that pair with the QIS on hospital-based medical cyclotrons. It files Drug Master Files (DMFs) with regulators that radiopharmaceutical innovators reference in their drug applications.
Is ARTMS a public or private company?
ARTMS is a private company. It is classified as corporate owned and is currently acquired.
When was ARTMS founded?
ARTMS was founded in 2013. It employs 11 to 50 people.
Where is ARTMS based?
ARTMS is headquartered in Vancouver, Canada, in the North America region.
How does ARTMS make money?
Four revenue lines are on record. QUANTM Irradiation System (QIS) Hardware Sales are the primary driver. The others are QUANTM Solid Target Consumables, regulatory/DMF Filing Services and technology Integration and Licensing to OEM Partners.
Who are ARTMS's main competitors?
Direct peers on record are IBA Radiopharma Solutions, NorthStar Medical Radioisotopes and SHINE Medical Technologies. Broad incumbents are Lantheus Holdings, Telix Pharmaceuticals, Curium Pharma and Bracco Imaging. Cardinal Health Nuclear Pharmacy Services is listed as a regional player. Emerging players are ITM Isotope Technologies Munich and PETNET Solutions (Siemens Healthineers).
Does ARTMS have an API?
No public API is recorded for ARTMS.
What industry is ARTMS in?
ARTMS's product category is Medical Isotope Production Equipment. Its primary akta.pro industry code is EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.), with a secondary code of EUAKAIAE, Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain). Its NAICS code is 334517 and its SIC code is 2835.